Lucid Diagnostics to Hold a Business Update Conference Call and Webcast on November 12, 2025

Lucid Diagnostics Inc. (Nasdaq: LUCD), a commercial-stage cancer prevention medical diagnostics enterprise and subsidiary of PAVmed Inc. (Nasdaq: PAVM), has announced a business update conference call and webcast scheduled for November 12, 2025, at 8:30 AM ET. The conference call aims to provide investors and stakeholders with key updates on the company’s operations and ongoing growth strategy. Lishan Aklog, M.D., the company’s Chairman and CEO, is set to present these developments, while Dennis McGrath, the Chief Financial Officer, will divulge the financial results for the third quarter of 2025.

Lucid Diagnostics is particularly focused on addressing the needs of patients suffering from gastroesophageal reflux disease (GERD), a condition that significantly increases the risk of developing esophageal precancer and cancer. The company has developed innovative diagnostic tools, including the EsoGuard® Esophageal DNA Test, which is designed to detect esophageal precancer efficiently and non-invasively. This test, which utilizes the EsoCheck® Esophageal Cell Collection Device, underscores Lucid's commitment to early cancer detection and prevention, offering hope for millions at risk.

The upcoming call and webcast will be accessible via the investor relations section of Lucid’s website (luciddx.com). For those who prefer the telephone option, U.S.-based participants can dial 1-800-836-8184, while international callers should use 1-646-357-8785, quoting the conference name "Lucid Diagnostics Business Update." Following the event, a replay will be available for 30 days on the company's website, ensuring that interested parties can access this crucial information. For further insights into Lucid Diagnostics and its parent company PAVmed, visit their respective websites.

Lucid Diagnostics Inc. (Nasdaq: LUCD) is set to hold a business update conference call and webcast on November 12, 2025, that could be pivotal for investors and stakeholders closely monitoring the company’s performance and strategic direction. As a commercial-stage cancer prevention medical diagnostics company, Lucid specializes in addressing the significant healthcare challenge presented by gastroesophageal reflux disease (GERD), which is linked to esophageal cancer.

During this conference, Dr. Lishan Aklog, CEO, and Dennis McGrath, CFO, will provide insights into the company’s operational updates and financial results for Q3 2025. Investors should pay keen attention to growth strategies and any developments surrounding their flagship products, including the EsoGuard® Esophageal DNA Test and EsoCheck® Esophageal Cell Collection Device. These products enable non-invasive early detection of esophageal precancer, representing a substantial advancement in preventive healthcare, thereby positioning Lucid favorably in a growing market.

Given the increasing emphasis on early cancer detection and prevention by healthcare providers and patients alike, Lucid Diagnostics has the potential to capitalize on this trend. Investors should analyze the company's revenue growth, market penetration rates, and any indications of increased adoption of its diagnostic tools post-update.

For current shareholders, maintaining a "hold" recommendation might be prudent ahead of the conference call. Anticipation of new information, particularly related to partnerships, clinical results, or regulatory milestones, could prompt increased volatility in the stock price. Therefore, staying engaged during this conference will be critical for assessing the company's trajectory and informing future investment decisions. Following the call, a comprehensive review of the financial results and strategic updates will be essential for gauging Lucid's long-term viability and market position.